Colorectal Cancer
Copyright ©The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2005; 11(28): 4332-4336
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4332
Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice
Volker Schmitz, Miroslaw Kornek, Tobias Hilbert, Christian Dzienisowicz, Esther Raskopf, Christian Rabe, Tilman Sauerbruch, Cheng Qian, Wolfgang H Caselmann
Volker Schmitz, Miroslaw Kornek, Tobias Hilbert, Christian Dzienisowicz, Esther Raskopf, Christian Rabe, Tilman Sauerbruch, Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Germany
Cheng Qian, Universidad de Navarra, Clinica Universitaria, Pamplona, Spain
Wolfgang H Caselmann, Bavarian State Ministry of the Environment, Public Health and Consumer Protection, Munich 81901, Germany
Author contributions: All authors contributed equally to the work.
Supported by the Deutsche Krebshilfe, No. 70-3065-SchmI
Correspondence to: Dr. Volker Schmitz, Medizinische Klinik I, Sigmund-Freud-Str. 25, Bonn 53105, Germany. volker.schmitz@ukb.uni-bonn.de
Telephone: +49-228-2876469 Fax: +49-228-2874698
Received: July 31, 2004
Revised: November 1, 2004
Accepted: November 4, 2004
Published online: July 28, 2005
Abstract

AIM: Tumor angiogenesis has been shown to be promoted by vascular endothelial growth factor (VEGF) via stimulating endothelial cell proliferation, migration, and survival. Blockade of VEGF signaling by different means has been demonstrated to result in reduced tumor growth and suppression of tumor angiogenesis in distinct tumor entities. Here, we tested a recombinant adenovirus, AdsFlt1-3, that encodes an antagonistically acting fragment of the VEGF receptor 1 (Flt-1), for systemic antitumor effects in pre-established subcutaneous CRC tumors in mice.

METHODS: Murine colorectal carcinoma cells (CT26) were inoculated subcutaneously into Balb/c mice for in vivo studies. Tumor size and survival were determined. 293 cell line was used for propagation of the adenoviral vectors. Human lung cancer line A549 and human umbilical vein endothelial cells were transfected for in vitro experiments.

RESULTS: Infection of tumor cells with AdsFlt1-3 resulted in protein secretion into cell supernatant, demonstrating correct vector function. As expected, the secreted sFlt1-3 protein had no direct effect on CT26 tumor cell proliferation in vitro, but endothelial cell function was inhibited by about 46% as compared to the AdLacZ control in a tube formation assay. When AdsFlt1-3 (5×109 PFU/animal) was applied to tumor bearing mice, we found a tumor inhibition by 72% at d 12 after treatment initiation. In spite of these antitumoral effects, the survival time was not improved. According to reduced intratumoral microvessel density in AdsFlt1-3-treated mice, the antitumor mechanism can be attributed to angiostatic vector effects. We did not detect increased systemic VEGF levels after AdsFlt1-3 treatment and liver toxicity was low as judged by serum alanine aminotransferase determination.

CONCLUSION: In this study we confirmed the value of a systemic administration of AdsFlt1-3 to block VEGF signaling as antitumor therapy in an experimental metastatic colorectal carcinoma model in mice.

Keywords: Colorectal carcinomas; Vascular endothelial growth factor; Systemic inhibition